Meanwhile, VEGF is a driver of tumor-related angiogenesis; several agents (e.g., bevacizumab) can antagonize VEGF-mediated signaling and improve progression-free survival when combined with cytotoxic chemotherapy for treating metastatic FBC [37]. Here, VEGFA is linked to complete blood cell count.